Moderna mRNA Melanoma Vaccine Plus Keytruda Shows Phase 3 Benefit
Aug 20
Breaking
3
On Wednesday, Aug. 19, 2026, Moderna said its personalized mRNA melanoma vaccine intismeran plus Merck's Keytruda helped patients live longer without cancer returning in a Phase 3 trial. PBS News After the announcement, Moderna shares more than doubled, rising over 120% to $140.12, while Merck shares rose about 11%. PBS News
